XLO Key Statistics, Chart & Performance
The current stock price of XLO is 0.6653 USD. In the past month the price decreased by -11.86%. In the past year, price decreased by -31.57%.
XLO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About XLO
Company Profile
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Company Info
XILIO THERAPEUTICS INC
828 Winter Street, Suite 300
Waltham MASSACHUSETTS US
Employees: 64
Phone: 16174304680
XILIO THERAPEUTICS INC / XLO FAQ
What does XILIO THERAPEUTICS INC do?
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
What is the current price of XLO stock?
The current stock price of XLO is 0.6653 USD. The price increased by 0.47% in the last trading session.
What is the dividend status of XILIO THERAPEUTICS INC?
XLO does not pay a dividend.
What is the ChartMill rating of XILIO THERAPEUTICS INC stock?
XLO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for XILIO THERAPEUTICS INC?
XILIO THERAPEUTICS INC (XLO) will report earnings on 2026-03-09, after the market close.
What is the Short Interest ratio of XILIO THERAPEUTICS INC (XLO) stock?
The outstanding short interest for XILIO THERAPEUTICS INC (XLO) is 23.23% of its float.
XLO Technical Analysis
XLO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XLO. While XLO seems to be doing ok healthwise, there are quite some concerns on its profitability.
XLO Financial Highlights
Over the last trailing twelve months XLO reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 68.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.02% | ||
| ROE | -795.33% | ||
| Debt/Equity | 0 |
XLO Forecast & Estimates
For the next year, analysts expect an EPS growth of 63.43% and a revenue growth 462.46% for XLO